Views & Analysis Dynamic consent models can benefit clinical trials Dynamic consent models for patients can develop ongoing partnership between participants and researchers.
News Syndax gets FDA okay for first-in-class leukaemia drug A few days after a disappointing clinical trial readout for Syndax Pharma's Revuforj in one form of leukaemia, the company has claimed FDA approval in another.
Digital Sponsored Decoding physician prescribing behaviour: A data-driven jour... Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge.
